行情

ADRO

ADRO

Aduro Biotech
NASDAQ

实时行情|Nasdaq Last Sale

1.120
-0.060
-5.08%
盘后: 1.130 +0.01 +0.89% 18:43 12/13 EST
开盘
1.180
昨收
1.180
最高
1.200
最低
1.110
成交量
181.09万
成交额
--
52周最高
4.590
52周最低
0.9011
市值
9,017.62万
市盈率(TTM)
-1.0012
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADRO 新闻

  • Hedge Funds Are Betting On Aduro BioTech Inc (ADRO)
  • Insider Monkey.11小时前
  • Does Aduro BioTech, Inc. (NASDAQ:ADRO) Have A Volatile Share Price?
  • Simply Wall St..5天前
  • Aduro Biotech (ADRO) Up 7.5% Since Last Earnings Report: Can It Continue?
  • Zacks.12/07 16:31
  • Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting
  • GlobeNewswire.11/08 21:05

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

ADRO 简况

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
展开

Webull提供Aduro BioTech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。